QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 wedbush-maintains-underperform-on-praxis-precision-medicine-raises-price-target-to-73

Wedbush analyst Daniel Ives maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Underperform and raises the price targe...

 truist-securities-reiterates-buy-on-praxis-precision-medicine-raises-price-target-to-360

Truist Securities analyst Joon Lee reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target...

 guggenheim-maintains-buy-on-praxis-precision-medicine-raises-price-target-to-350

Guggenheim analyst Yatin Suneja maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target fro...

 chardan-capital-maintains-buy-on-praxis-precision-medicine-raises-price-target-to-330

Chardan Capital analyst Rudy Li maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target fro...

 deutsche-bank-maintains-buy-on-praxis-precision-medicine-raises-price-target-to-280

Deutsche Bank analyst David Hoang maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target f...

 praxis-precision-medicines-announces-proposed-public-offering-no-terms-disclosed

Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into th...

 needham-maintains-buy-on-praxis-precision-medicine-raises-price-target-to-250

Needham analyst Ami Fadia maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $80 ...

 praxis-precision-medicines-stock-doubles---heres-why

Praxis stock jumps after Phase 3 trials show ulixacaltamide significantly improves essential tremor symptoms and meets key effi...

 praxis-precision-medicines-ulixacaltamide-hcl-study-1-for-essential-tremor-met-primary-endpoint-all-key-secondary-endpoints-in-study-1-were-also-statistically-significant

Patients treated with ulixacaltamide in the parallel-group study (Study 1) showed a mean improvement from baseline in the Modif...

 praxis-precision-reports-phase-3-results-for-ulixacaltamide-in-essential-tremor

Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into th...

 jones-trading-initiates-coverage-on-praxis-precision-medicine-with-buy-rating-announces-price-target-of-83

Jones Trading analyst Justin Walsh initiates coverage on Praxis Precision Medicine (NASDAQ:PRAX) with a Buy rating and annou...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION